Effect of L. Reuteri NCIMB 30242 on Plasma Bile Acid Profile

Hypercholesterolemia Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02216825
• Other study ID #: MP-12LCHMe
• Status: Completed
• Phase: Phase 2
• First received: August 12, 2014
• Last updated: August 12, 2014
• Start date: November 2013
• Est. completion date: June 2014

Study information

• Verified date: June 2014
• Source: Micropharma Limited
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

Background: In recent years, probiotics have shown promise in treating a variety of diseases. Previously, the investigators have reported on the clinical efficacy of bile salt hydrolase active Lactobacillus reuteri NCIMB 30242 in improving the lipid profile in hypercholesterolemic adults.

Objective: The purpose of the study is to investigate the effect of a delayed release or standard vegetarian capsule containing L. reuteri NCIMB 30242, taken in escalated dose over a 4 week period, on the plasma bile acid profile.

Design: The study design is a pilot, randomized, double-blind, dose-escalation study. The study will last a total of 6 weeks, including a 4-week intervention period and a 2-week washout period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: June 2014
• Est. primary completion date: December 2013
• Gender: Both
• Age group: 20 Years to 75 Years

Eligibility

Inclusion Criteria:

• Males and females, aged 20 to 75 years (bounds included).

• LDL-C = 3.40 mmol/L.

• TG < 4.00 mmol/L.

• TBA < 10 umol/L.

• BMI range from 23.0 to 32.5 kg/m2 (bounds included).

• Signed informed consent form prior to inclusion in the study.

• Note: Subjects will be permitted to take stable doses of thyroid hormone and anti-hypertensive agents, as long as these are continued equivalently throughout the duration of study.

• Female subjects not of child bearing potential. Defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation) OR Female subject of childbearing potential who agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include: Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System); Intrauterine devices; Vasectomy of partner; Total abstinence.

Exclusion Criteria:

• Use of cholesterol lowering prescription drugs within the last 6 months.

• Use of plant sterols, omega 3, fish oil, soy protein, soluble oat fiber, psyllium seed husk, or other cholesterol lowering non-prescription supplements within last 1 month.

• History of chronic use of alcohol (> 2 drinks/d).

• History of heavy smoking (= 20 cigarettes/d).

• Use of systemic antibodies, corticosteroids, androgens, or phenytoin.

• Immune-compromised subjects (e.g. AIDS, lymphoma, subjects undergoing long-term corticosteroid treatment)

• Subject having experienced any cardiovascular event (Myocardial infarction, coronary artery bypass, or other major surgical procedures) in the last 6 months.

• Subjects with elevated LDL-C (= 3.40 mmol/L) and high (>20%) CVD risk estimated by the Framingham risk score

• Previously diagnosed Type I or Type II diabetes.

• Subject receiving systemic treatment or topical treatment likely to interfere with evaluation of the study parameters.

• Subject currently involved in a clinical trial or in an exclusion period following participation in another clinical trial.

• History of angina, congestive heart failure, inflammatory bowel disease, pancreatitis, gastrointestinal, renal, pulmonary, hepatic or biliary disease, or cancer (evidence of active lesions, chemotherapy or surgery in the past year).

• Clinically significant abnormal laboratory results at screening.

• Chronic user of probiotics or fibre laxative (greater than 2 doses/wk), or stimulant laxatives.

• History of eating disorders.

• Exercise greater than 15 miles/wk or 4,000 kcal/wk.

• Female subjects that are pregnant, breast feeding or intend to get pregnant.

• Allergy or sensitivity to test product ingredients

• Allergy or sensitivity to all 3 antibiotics (Clindamycin, Erythromycin and Ampicillin).

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)

Related Conditions & MeSH terms

• Hypercholesterolemia

Intervention

Dietary Supplement:
• Delayed release capsule, L. reuteri NCIMB 30242, escalated dose

• Standard vegetarian capsule, L. reuteri NCIMB 30242, escalated dose

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Micropharma Limited

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary outcome will be the change in plasma bile acid profile from baseline to endpoint		Week 0 and Week 4 of intervention period	No